Every 10-K that Autonomix Medical, Inc. (AMIX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow AMIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMIX filings page.
Autonomix Medical, Inc. files an amendment to its annual report to add detailed Part III information on directors, executive compensation, ownership, related-party oversight, and auditor fees. The company reports aggregate market value of non‑affiliate voting equity of $6,307,279 and 11,409,344 shares outstanding as of June 10, 2026.
For fiscal 2026, CEO Brad Hauser received total compensation of $670,176, while Vice Chair Lori Bisson and CFO Trent Smith received $204,000 and $381,763, respectively. The filing describes board committee structures, independence determinations, anti‑hedging and insider trading policies, a Dodd‑Frank–style recoupment policy, and outlines equity plans and option cancellations that left named executive officers and non‑employee directors with no outstanding equity awards as of March 31, 2026.
Autonomix Medical, Inc. is a development-stage medical device company building a catheter-based system that can sense tiny peripheral nerve signals and deliver targeted radiofrequency ablation, aiming for a “sense, treat, verify” workflow initially focused on pancreatic cancer pain.
The company sees large potential markets across pain management, hypertension and other nerve-related disorders, but currently has no approved products or product revenue and depends on third-party manufacturers. It plans a De Novo FDA pathway, with U.S. IDE trials anticipated to start in late 2026 using its proprietary sensing and ablation catheters.
As of March 31, 2026, Autonomix had an accumulated deficit of $67.1 million, negative operating cash flow of $12.3 million, and working capital of $5.9 million, which raises substantial doubt about its ability to continue as a going concern without new financing. Management believes existing capital lasts into the fourth calendar quarter of 2026 and highlights significant regulatory, clinical, manufacturing, cybersecurity and Nasdaq listing risks.